Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB502234258

Publication Date:

February 22, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. In some cases, it prevents the heart from relaxing and filling with blood as it should.
Highlights
The global Dilated Cardiomyopathy Therapeutics market was valued at US$ 29 million in 2022 and is anticipated to reach US$ 34 million by 2029, witnessing a CAGR of 2.7% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Dilated Cardiomyopathy Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Dilated Cardiomyopathy Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Dilated Cardiomyopathy Therapeutics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Dilated Cardiomyopathy Therapeutics include Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithkline Plc, Johnson and Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure, GmbH and Teva Pharmaceutical Industries, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Dilated Cardiomyopathy Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dilated Cardiomyopathy Therapeutics.
The Dilated Cardiomyopathy Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Dilated Cardiomyopathy Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dilated Cardiomyopathy Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Aastrom Biosciences
Capricor Therapeutics
GlaxoSmithkline Plc
Johnson and Johnson
Kasiak Research Pvt. Ltd.
Merck & Co., Inc.
MyoKardia, Pfizer, Inc.
t2cure, GmbH
Teva Pharmaceutical Industries
ZensunSci & Tech
Segment by Type
Drug Class
Implantable Device
Pipeline Analysis
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dilated Cardiomyopathy Therapeutics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Drug Class
1.2.3 Implantable Device
1.2.4 Pipeline Analysis
1.3 麻豆原创 by Application
1.3.1 Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Dilated Cardiomyopathy Therapeutics Growth Trends by Region
2.2.1 Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Dilated Cardiomyopathy Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Dilated Cardiomyopathy Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Dilated Cardiomyopathy Therapeutics 麻豆原创 Dynamics
2.3.1 Dilated Cardiomyopathy Therapeutics Industry Trends
2.3.2 Dilated Cardiomyopathy Therapeutics 麻豆原创 Drivers
2.3.3 Dilated Cardiomyopathy Therapeutics 麻豆原创 Challenges
2.3.4 Dilated Cardiomyopathy Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dilated Cardiomyopathy Therapeutics Players by Revenue
3.1.1 Global Top Dilated Cardiomyopathy Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Dilated Cardiomyopathy Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dilated Cardiomyopathy Therapeutics Revenue
3.4 Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Dilated Cardiomyopathy Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dilated Cardiomyopathy Therapeutics Revenue in 2022
3.5 Dilated Cardiomyopathy Therapeutics Key Players Head office and Area Served
3.6 Key Players Dilated Cardiomyopathy Therapeutics Product Solution and Service
3.7 Date of Enter into Dilated Cardiomyopathy Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Dilated Cardiomyopathy Therapeutics Breakdown Data by Type
4.1 Global Dilated Cardiomyopathy Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Dilated Cardiomyopathy Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Dilated Cardiomyopathy Therapeutics Breakdown Data by Application
5.1 Global Dilated Cardiomyopathy Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Dilated Cardiomyopathy Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Dilated Cardiomyopathy Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Dilated Cardiomyopathy Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dilated Cardiomyopathy Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Dilated Cardiomyopathy Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dilated Cardiomyopathy Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Dilated Cardiomyopathy Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dilated Cardiomyopathy Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Dilated Cardiomyopathy Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dilated Cardiomyopathy Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Dilated Cardiomyopathy Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Dilated Cardiomyopathy Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Aastrom Biosciences
11.1.1 Aastrom Biosciences Company Detail
11.1.2 Aastrom Biosciences Business Overview
11.1.3 Aastrom Biosciences Dilated Cardiomyopathy Therapeutics Introduction
11.1.4 Aastrom Biosciences Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.1.5 Aastrom Biosciences Recent Development
11.2 Capricor Therapeutics
11.2.1 Capricor Therapeutics Company Detail
11.2.2 Capricor Therapeutics Business Overview
11.2.3 Capricor Therapeutics Dilated Cardiomyopathy Therapeutics Introduction
11.2.4 Capricor Therapeutics Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.2.5 Capricor Therapeutics Recent Development
11.3 GlaxoSmithkline Plc
11.3.1 GlaxoSmithkline Plc Company Detail
11.3.2 GlaxoSmithkline Plc Business Overview
11.3.3 GlaxoSmithkline Plc Dilated Cardiomyopathy Therapeutics Introduction
11.3.4 GlaxoSmithkline Plc Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.3.5 GlaxoSmithkline Plc Recent Development
11.4 Johnson and Johnson
11.4.1 Johnson and Johnson Company Detail
11.4.2 Johnson and Johnson Business Overview
11.4.3 Johnson and Johnson Dilated Cardiomyopathy Therapeutics Introduction
11.4.4 Johnson and Johnson Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.4.5 Johnson and Johnson Recent Development
11.5 Kasiak Research Pvt. Ltd.
11.5.1 Kasiak Research Pvt. Ltd. Company Detail
11.5.2 Kasiak Research Pvt. Ltd. Business Overview
11.5.3 Kasiak Research Pvt. Ltd. Dilated Cardiomyopathy Therapeutics Introduction
11.5.4 Kasiak Research Pvt. Ltd. Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.5.5 Kasiak Research Pvt. Ltd. Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Dilated Cardiomyopathy Therapeutics Introduction
11.6.4 Merck & Co., Inc. Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.6.5 Merck & Co., Inc. Recent Development
11.7 MyoKardia, Pfizer, Inc.
11.7.1 MyoKardia, Pfizer, Inc. Company Detail
11.7.2 MyoKardia, Pfizer, Inc. Business Overview
11.7.3 MyoKardia, Pfizer, Inc. Dilated Cardiomyopathy Therapeutics Introduction
11.7.4 MyoKardia, Pfizer, Inc. Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.7.5 MyoKardia, Pfizer, Inc. Recent Development
11.8 t2cure, GmbH
11.8.1 t2cure, GmbH Company Detail
11.8.2 t2cure, GmbH Business Overview
11.8.3 t2cure, GmbH Dilated Cardiomyopathy Therapeutics Introduction
11.8.4 t2cure, GmbH Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.8.5 t2cure, GmbH Recent Development
11.9 Teva Pharmaceutical Industries
11.9.1 Teva Pharmaceutical Industries Company Detail
11.9.2 Teva Pharmaceutical Industries Business Overview
11.9.3 Teva Pharmaceutical Industries Dilated Cardiomyopathy Therapeutics Introduction
11.9.4 Teva Pharmaceutical Industries Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.9.5 Teva Pharmaceutical Industries Recent Development
11.10 ZensunSci & Tech
11.10.1 ZensunSci & Tech Company Detail
11.10.2 ZensunSci & Tech Business Overview
11.10.3 ZensunSci & Tech Dilated Cardiomyopathy Therapeutics Introduction
11.10.4 ZensunSci & Tech Revenue in Dilated Cardiomyopathy Therapeutics Business (2018-2023)
11.10.5 ZensunSci & Tech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Aastrom Biosciences
Capricor Therapeutics
GlaxoSmithkline Plc
Johnson and Johnson
Kasiak Research Pvt. Ltd.
Merck & Co., Inc.
MyoKardia, Pfizer, Inc.
t2cure, GmbH
Teva Pharmaceutical Industries
ZensunSci & Tech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.